Nomograms to predict progression of disease within 24 months in patients with localized natural killer/T-cell lymphoma.
Future Oncol
; 18(32): 3573-3583, 2022 Oct.
Article
em En
| MEDLINE
| ID: mdl-36507722
ABSTRACT
Aims:
Progression of disease within 24 months (POD24) is associated with poor survival in some subtypes of lymphoma.The aim is to identify high-risk patients with localized extranodal natural killer/T-cell lymphoma (ENKTL) and to define clinical factors associated with the risk of early recurrence after antitumor treatment.Methods:
The authors retrospectively analyzed 330 cases with localized ENKTL, of which 89 experienced POD24.Results:
The 5-year overall survival of the POD24 group was extremely inferior to that of the non-POD24 group. Risk factors for POD24 were Eastern Cooperative Oncology Group performance status ≥2, response evaluation (non-complete remission) after first-line treatment and elevated lactate dehydrogenase concentrations. Also, higher Epstein-Barr virus DNA titer was related to POD24. Based on these data with or without the availability of Epstein-Barr virus DNA, the authors conducted two nomograms to predict POD24, which showed good accuracy with high C statistics.Conclusion:
The results showed that POD24 could serve as a marker to identify patients whose medical needs were unmet in ENKTL.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por Vírus Epstein-Barr
/
Linfoma Extranodal de Células T-NK
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
China